tetano
Editor, Senior Moderator
Influenza Other Respir Viruses
. 2025 May;19(5):e70102.
doi: 10.1111/irv.70102. Low Levels of Neutralizing Antibodies Against SARS-CoV-2 KP.3.1.1 and XEC in Serum From Seniors in May 2024
Even Fossum[SUP] 1 [/SUP], Elisabeth Lea Vikse[SUP] 1 [/SUP], Anna Hayman Robertson[SUP] 2 [/SUP], Asia-Sophia Wolf[SUP] 2 [/SUP], Andreas Rohringer[SUP] 1 [/SUP], Lill Trogstad[SUP] 2 [/SUP], Siri Mjaaland[SUP] 2 [/SUP], Olav Hungnes[SUP] 1 [/SUP], Karoline Bragstad[SUP] 1 [/SUP]
Affiliations
New immune evasive variants of SARS-CoV-2 may increase infections and hospitalizations in risk groups, such as the elderly. In this study, we evaluated neutralizing antibodies against KP.3.1.1 and XEC, virus variants that were either widely distributed or on the rise globally in the fall of 2024, in sera from a cohort of seniors aged 68-82 years collected in April/May 2024. Neutralizing responses were low against both KP.3.1.1 and XEC, also in XBB.1.5 boosted individuals and people with recent break-through infections, supporting the recommendation of an updated COVID-19 vaccine booster in this age group.
Keywords: KP.3.1.1; SARS‐CoV‐2; XEC; elderly; immunity; neutralizing antibodies.
. 2025 May;19(5):e70102.
doi: 10.1111/irv.70102. Low Levels of Neutralizing Antibodies Against SARS-CoV-2 KP.3.1.1 and XEC in Serum From Seniors in May 2024
Even Fossum[SUP] 1 [/SUP], Elisabeth Lea Vikse[SUP] 1 [/SUP], Anna Hayman Robertson[SUP] 2 [/SUP], Asia-Sophia Wolf[SUP] 2 [/SUP], Andreas Rohringer[SUP] 1 [/SUP], Lill Trogstad[SUP] 2 [/SUP], Siri Mjaaland[SUP] 2 [/SUP], Olav Hungnes[SUP] 1 [/SUP], Karoline Bragstad[SUP] 1 [/SUP]
Affiliations
- PMID: 40369880
- DOI: 10.1111/irv.70102
New immune evasive variants of SARS-CoV-2 may increase infections and hospitalizations in risk groups, such as the elderly. In this study, we evaluated neutralizing antibodies against KP.3.1.1 and XEC, virus variants that were either widely distributed or on the rise globally in the fall of 2024, in sera from a cohort of seniors aged 68-82 years collected in April/May 2024. Neutralizing responses were low against both KP.3.1.1 and XEC, also in XBB.1.5 boosted individuals and people with recent break-through infections, supporting the recommendation of an updated COVID-19 vaccine booster in this age group.
Keywords: KP.3.1.1; SARS‐CoV‐2; XEC; elderly; immunity; neutralizing antibodies.